Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6605cbdc52e28220a0cebc63a861bcea |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6873 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6897 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6817 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-537 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-50 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5386 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 |
filingDate |
2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08920abb3d7372b1b3986d4f6d180154 |
publicationDate |
2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-111787923-A |
titleOfInvention |
Anti-CD22 Antibody-Maytansinoids Conjugates, Combinations, and Methods of Using the Same |
abstract |
The present disclosure provides methods of treating cancer or resistant cancer with a combination of an anti-CD22 antibody-maytansinoid conjugate and one or more anticancer agents. The present disclosure also encompasses methods of sensitizing cancer with such combinations. Also provided are pharmaceutical compositions comprising such combinations. |
priorityDate |
2017-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |